Israel Chemicals Ltd. (NYSE:ICL) announced its earnings results on Wednesday. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. Israel Chemicals had a return on equity of 17.44% and a net margin of 7.40%. The firm earned $1.38 billion during the quarter. During the same period in the prior year, the business earned $0.12 earnings per share. The company’s revenue for the quarter was up .3% compared to the same quarter last year.
Shares of Israel Chemicals (NYSE:ICL) traded down 2.63% during midday trading on Friday, hitting $3.70. The stock had a trading volume of 38,070 shares. Israel Chemicals has a 12 month low of $3.52 and a 12 month high of $5.23. The stock has a market cap of $4.71 billion, a PE ratio of 11.67 and a beta of 1.14. The stock’s 50-day moving average is $3.74 and its 200-day moving average is $3.99.
Several large investors have recently added to or reduced their stakes in ICL. Jarislowsky Fraser Ltd raised its stake in Israel Chemicals by 3.1% in the second quarter. Jarislowsky Fraser Ltd now owns 29,084 shares of the company’s stock valued at $113,000 after buying an additional 887 shares in the last quarter. Barclays PLC raised its stake in Israel Chemicals by 122.1% in the first quarter. Barclays PLC now owns 85,017 shares of the company’s stock valued at $340,000 after buying an additional 46,732 shares in the last quarter. Public Sector Pension Investment Board raised its stake in Israel Chemicals by 19.0% in the second quarter. Public Sector Pension Investment Board now owns 96,656 shares of the company’s stock valued at $374,000 after buying an additional 15,400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Israel Chemicals by 32.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 99,216 shares of the company’s stock valued at $386,000 after buying an additional 24,505 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in Israel Chemicals during the second quarter valued at $803,000. Institutional investors own 6.51% of the company’s stock.
Separately, Zacks Investment Research raised Israel Chemicals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Monday.